Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC. Intratumoral recombinant GM-CSF encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther, 6(5):409-22, 1999.

Yang AS, Monken CE and Lattime EC. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res, 63(20):6956-61, 2003.

de Vries CR, Monken CE, and Lattime EC. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Therapy, 22(3):154-162, 2015. PMC4397129

de Vries CR, Kaufman HL, Lattime EC, Oncolytic viruses: Focusing on the tumor microenvironment. Cancer Gene Therapy 22(4)169171, 2015. 

DiPaola RS, Chen Y-H, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley J, Arlen PM, Butterfield LH, Wilding G. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. Eur. Urol. (Epub ahead of print), 2015.

Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kuehner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, MonkenCE, Shafikhani S, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenis acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Reports, 17:957-965, 2016. 

Sharp, DW and Lattime EC, Recombinant poxvirus and the tumor microenvironment: Oncolysis, immune regulation and Immunization. Biomedicines 4:19, 2016.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman H, Lattime EC, Mehnert J, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S.  Identifying a clinically applicable mutation burden threshold as a biomarker of response to immune checkpoint therapy of solid tumors. J. Clin. Oncol Precision Oncol. (Published Online 12/2017).